 
                                               
                                              The UC Davis Comprehensive Cancer Center participated in a phase III clinical research to explore if the anti-cancer medication everolimus helped persons with kidney cancer. The clinical study findings revealed that many patients with kidney cancer survived for several years after undergoing surgery to remove the tumour.
The study also found that in a group of individuals at high risk of relapse, everolimus may have kept them cancer-free for a longer period of time. The findings were reported in The Lancet on July 28.
Primo “Lucky” Lara, Jr., Director of the Cancer Center, was a key investigator in the SWOG Cancer Research Network’s phase III S0931 experiment, better known as the EVEREST study.
Lara is SWOG’s deputy group chair and was recently appointed co-chair elect of the National Cancer Institute’s (NCI) cancer clinical trials group. Christopher W. Ryan, a SWOG investigator and professor of medicine at Oregon Health & Science University, led the study.
The study included patients from roughly 400 cancer centers around the country, including several from UC Davis Comprehensive Cancer Center. For 54 weeks, they were given 10 milligrams of oral everolimus or a placebo.
“Improvement was seen primarily in patients with very high-risk disease, while patients with intermediate high-risk disease saw no improvement,” Lara said. “This encouraging observation warrants further study. We must continue our work to discover and test new agents to improve outcomes in people with kidney cancer.”
Everolimus belongs to a class of drugs known as mTOR inhibitors, which prevent the growth of malignant cells.
Similar medicines are already being utilized to enhance the results of other cancer patients who have undergone surgery, including breast cancer patients.
The EVEREST trial enrolled 1,545 patients with intermediate high-risk or very high-risk renal cell carcinoma (cancer of the lining of the kidney tubes). Their cancer had all been medically removed with a partial or radical nephrectomy (kidney removal).
“Recurrence of cancer in these patients ranges from 2% to 40% following surgery,” Lara said. “It is important to test active new agents as part of clinical trials after their surgery and before their cancer returns and spreads.”
more recommended stories
 Meniscal Tear and OA Pain Improved by Home Exercise Meniscal Tear and OA Pain Improved by Home Exercise- Home Exercise Proves Effective for Knee. 
 AI ECG Model Outperforms Standard STEMI Triage AI ECG Model Outperforms Standard STEMI Triage- Novel AI ECG Model Outperforms Standard. 
 New Software Transforms Real-Time Pathogen Surveillance New Software Transforms Real-Time Pathogen Surveillance- Real-Time Pathogen Surveillance Software Transforms Environmental. 
 Bright Nights May Increase Stroke, Heart Failures in Adults Bright Nights May Increase Stroke, Heart Failures in Adults- Bright Nights are tied to increased. 
 Cannabis Use Linked to Regular Tobacco in US Youth Cannabis Use Linked to Regular Tobacco in US Youth- Cannabis Use and Tobacco Risk: A. 
 Mediterranean Diet Reduces Endometriosis Risk in Women Mediterranean Diet Reduces Endometriosis Risk in Women- Mediterranean Diet and Endometriosis: A Promising. 
 Night Shifts May Trigger Irritable Bowel Syndrome (IBS) Night Shifts May Trigger Irritable Bowel Syndrome (IBS)- Night Shifts and Digestive Health: Linking. 
 Blood test shows promise for faster ALS diagnosis Blood test shows promise for faster ALS diagnosis- Summary / Key Points A UCLA. 
 Caraway seed chemistry yields anticonvulsant leads Caraway seed chemistry yields anticonvulsant leads- A team led by UNLV researchers. 
 Quitting Smoking Slows Memory Decline, Study Finds Quitting Smoking Slows Memory Decline, Study Finds- Quitting smoking is linked to slower. 

Leave a Comment